High doses of prochlorperazine for cisplatin-induced emesis. A prospective, random, dose-response study

B. I. Carr, D. W. Blayney, D. A. Goldberg, P. Braly, G. E. Metter, J. H. Doroshow

Research output: Contribution to journalArticlepeer-review

Abstract

This study investigated the antiemetic properties of four different doses of prochlorperazine (10 mg, 20 mg, 30 mg, 40 mg) when given randomly to patients receiving four cycles of the same dose of cisplatin-based chemotherapy. Prochlorperazine was given to 71 patients by slow intravenous infusion 30 minutes before and 3 and 6 hours after the start of cisplatin chemotherapy. The higher doses of prochlorperazine proved to be effective in the control of cisplatin-induced emesis. For the 20 patients who completed all 4 study cycles of treatment, a relationship was discerned between the dose of prochlorperazine administered and the antiemetic effect. When all 71 patients were analyzed in terms of the results of the first cycle of chemotherapy, a significant dose-response effect was also found. Overall toxic reactions in 82 treatment cycles using either 30 mg or 40 mg of prochlorperazine were dystonia (1 patient), restlessness (2), hypotension (3), and drowsiness (12). This study demonstrates that higher-than-conventional doses of prochlorperazine have an impressive antinauseant effect with only moderate toxicity.

Original languageEnglish
Pages (from-to)2165-2169
Number of pages5
JournalCancer
Volume60
Issue number9
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'High doses of prochlorperazine for cisplatin-induced emesis. A prospective, random, dose-response study'. Together they form a unique fingerprint.

Cite this